Due to osteoporosis, bones are thinner and more fragile, which increases the number of fractures, especially in the hip. Due to the fact that this illness is a serious individual and social problem in today's world, it is therefore extremely important to diagnose it correctly and apply the appropriate treatment. This treatment, usually, is based on some general measures combined with other pharmacological ones, among which these are worthy to note: administering calcium and vitamin D and substitute hormone therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trabecular bone deficits predominate in the appendicular skeleton of midlife women living with HIV: findings from a cross-sectional study in Zimbabwe.
J Bone Miner Res
January 2025
MRC Lifecourse Epidemiology Centre, Human Development and Health, University of Southampton, Southampton, United Kingdom.
HIV-related mortality has fallen due to scale-up of antiretroviral therapy (ART), so more women living with HIV (WLH) now live to reach menopause. Menopausal estrogen loss causes bone loss, as do HIV and certain ART regimens. However, quantitative bone data from WLH are few in Africa.
View Article and Find Full Text PDFNrf2 Activation as a Therapeutic Target for Flavonoids in Aging-Related Osteoporosis.
Nutrients
January 2025
College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL 32307, USA.
Biological aging is a substantial change that leads to different diseases, including osteoporosis (OP), a condition involved in loss of bone density, deterioration of bone structure, and increased fracture risk. In old people, there is a natural decline in bone mineral density (BMD), exacerbated by hormonal changes, particularly during menopause, and it continues in the early postmenopausal years. During this transition time, hormonal alterations are linked to elevated oxidative stress (OS) and decreased antioxidant defenses, leading to a significant increase in OP.
View Article and Find Full Text PDFDecrease in Facial Bone Density with Aging and Maintenance Effect of Calcium Maltobionate Ingestion in Japanese Adult Women: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
Nutrients
January 2025
Graduate School of Bioscience and Biotechnology, Chubu University, 1200, Matsumoto-cho, Kasugai-city 487-8501, Aichi, Japan.
Background/objectives: Facial bone density, including the jawbone, declines earlier than that of the lumbar spine and calcaneus. Calcium maltobionate is reported to mitigate bone resorption and maintain bone density of the lumbar spine in post-menopausal women, but its effects on facial bone density remain understudied. Therefore, this study compared variations in facial bone mineral density with variations in calcaneal bone mineral density and bone resorption markers among healthy women, examining differences between pre- and post-menopause and the effects of continuous calcium maltobionate intake.
View Article and Find Full Text PDFA Real-Life Study in Sequential Therapy for Severe Menopausal Osteoporosis.
J Clin Med
January 2025
Department of Endocrinology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Teriparatide (TPT) acts against severe primary (postmenopausal) osteoporosis (MOP), and it requires continuation with another anti-resorptive drug to conserve or enhance the effects on fracture risk reduction. To analyse the sequential pharmacotherapy in MOP who were treated upon a 24-month daily 20 µg TPT protocol (24-mo-TPT) followed by another 12 months of anti-resorptive drugs (12-mo-AR) amid real-life settings. 1.
View Article and Find Full Text PDFEffects of key physiological parameters on cardiovascular disease and osteoporosis risk in perimenopausal and postmenopausal women.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
The essential cause of menopause is ovarian failure, which can cause decline in sex hormones (especially estrogen) that can increase the risk of metabolic diseases, such as cardiovascular disease and osteoporosis. This study screened 1511 eligible patients from 2148 perimenopausal and postmenopausal women, measuring various physiological and biochemical indicators to analyze differences among age groups (40-44, 45-49, and 50-54 years) with laboratory techniques. The study found no significant difference in the incidence of cardiovascular disease betweenperimenopausal and postmenopausal women.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!